← FDA DRUG APPROVALS

FDA ANDA · ANDA210614

NIFEDIPINE

Sponsor: NOVAST LABS

APPLICATION
ANDA210614
TYPE
ANDA
ORIGINAL APPROVAL
2019-03-12
LATEST ACTION
2019-03-12
ROUTE
ORAL
DOSAGE FORM
TABLET, EXTENDED RELEASE
MARKETING STATUS
Prescription

Products

NIFEDIPINEPrescription
NIFEDIPINE 60MG · TABLET, EXTENDED RELEASE · ORAL
NIFEDIPINEPrescription
NIFEDIPINE 90MG · TABLET, EXTENDED RELEASE · ORAL
NIFEDIPINEPrescription
NIFEDIPINE 30MG · TABLET, EXTENDED RELEASE · ORAL

Approval history

2019-03-12UNKNOWN · Original · standardAP
VIEW ON DRUGS@FDA ↗

Related on SPEQ

Pharma industry →GMP discipline →FDA drug shortages →FDA enforcement & recalls →

Source: FDA Drugs@FDA. SPEQ is not affiliated with the FDA; this is a reference view of public FDA data, not medical, legal, or regulatory advice.

Weekly Briefing

Get the Weekly GxP Briefing

Curated regulatory intelligence — enforcement, recalls, guidance, and quality signals — in one practitioner-grade email each week. Free.

Read a past issue →